Article Text

SAT0451 The one-year radiographic progression and minimal disease activity in early psoriatic arthritis patients treated according to treat-to-target strategy (results of an ongoing open-label remarca study)
  1. E Loginova,
  2. T Korotaeva,
  3. A Smirnov,
  4. A Koltakova,
  5. D Karateev
  1. V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation


Background Treat-to-target (T2T) strategy has benefit in early psoriatic arthritis (EPsA) treatment. Its influence on radiographic progression has limited data.

Objectives to investigate radiographic outcomes and minimal disease activity (MDA) after 1-year of T2T strategy in patients with EPsA.

Methods 40 (M-18/F-22) DMARD-naïve pts with active EPsA, according to the CASPAR criteria, mean age 38.4±11.1 yrs., PsA duration 11.9±10.6 months, psoriasis duration 73.8±84.6 months, median DAS 3.8 [3.2; 4.7] from the open-label REMARCA study were included. At baseline all pts were treated by Methotrexate (MTX) subcutaneous (s/c) 20–25 mg/week. Pts that still had medium or high activity after 3–6 months were treated by combination therapy MTX+ biologic therapy (BT) - anti-TNF or Ustekinumab (n=21). By the end of the study, 19 pts were treated by MTX-monotherapy. At baseline and after 1-yr. of treatment PsA activity index and digital radiographs of hands and feet were performed. All images were scored according to Sharp/van der Heijde (Sh.-v.d. H) method by a blinded musculoskeletal radiologist. Median total score (TS Sh.-v.d. H) = total erosion score (TES) + total narrowing score (TNS), the proportion of pts who reached MDA, M±SD, Me [Q75; Q50], W-test, U-test, (%) were calculated. All p<0.05 were considered to indicate statistical significance.

Results At baseline, 23 out of 40 pts (57%) had erosion. By 1 yr., the number of pts with erosion increased up to 26 pts (65%). The median TS Sh.-v.d. H significantly increased from 91.5 [72–108.5] to 91.5 [73.5–111.5] (W-test, p<0.01), TES from 2 [0–4.5] to 2.5 [0–5] (W-test, p<0.05) and TNS from 85 [69–105] to 87 [71.5–107] (W-test, p<0.01). At 1 yr. of therapy there was no significant difference between the treatment groups in the value of TS Sh.-v.d. H (W-test p>0.05).

25 of pts (62.5%) had reached MDA by 1 yr. In pts who did not reach MDA (n=15) by 1 yr. TES was significantly higher at baseline compare to those who reached MDA: 3 [2–9] and 0 [0–3] accordingly (U-test, p<0.05). In the group of pts who did not reach MDA 1 yr. progression was significantly higher (table).

Table 1

In 29 out of 40 pts (72.5%) there was no X-ray progression considering both erosion and joint space narrowing. 13 of them (45%) were treated by MTX and 16 pts (55%) by MTX+BT. Negative X-ray progression was found in 11 out of 40 pts (27.5%): 6 of them (54.5%) were treated by MTX and 5 pts (45.5%) by MTX+BT.

Conclusions In the Russian cohort of active EPsA pts erosion was found in more than half of cases. Active EPsA pts treated according to T2T strategy during 1 year in 72.5% did not show any radiographic progression, only a quarter of pts (27.5%) had negative X-ray progression by the end of the study, regardless of the type of therapy. The pts who achieved MDA had less erosive progression.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.